Novo Nordisk Shows It Is Ready To Extend Its Obesity Portfolio

Novel Oral Obesity Drug Shows Promise

During a capital markets day, the company highlighted Phase I weight loss data for its novel oral obesity drug amycretin, which could work in a complementary fashion to GLP-1s. 

scale
Novo Nordisk revealed new obesity drug data • Source: Shutterstock

Novo Nordisk A/S revealed encouraging efficacy data for a novel oral obesity medicine during a capital market day on 7 March, intriguing investors who are aware the company will need to deliver next-generation advances in obesity to maintain its leadership position in the competitive therapeutic area.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success

 

The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.